Evidence map›Paper›PMID 40031089›Full record

ArticleVaccine2025

Designing a National Rapid Vaccine Coverage Survey in low-resource settings: Experiences from the Democratic Republic of the Congo 2018-2023.

Eric M Mafuta, Aimée M Lulebo, Jean-Bosco N Kasonga, Nono M Mvuama, Christophe L Luhata, Nicole A Hoff, Dalau M Nkamba, Sydney Merritt, John Samuel Otomba, Branly K Mbunga and 15 more

Abstract read
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Eric M MafutaKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo. Electronic address: eric.mafuta@unikin.ac.cd.
Aimée M LuleboKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Jean-Bosco N KasongaKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Nono M MvuamaKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Christophe L LuhataExpanded Program for Vaccination, Minister of Public Health, Hygiene and Prevention, Kinshasa, Democratic Republic of the Congo.
Nicole A HoffUniversity of California Los Angeles, Department of Epidemiology, CA, Los Angeles, USA.
Dalau M NkambaKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Sydney MerrittUniversity of California Los Angeles, Department of Epidemiology, CA, Los Angeles, USA.
John Samuel OtombaWorld Health Organization, DRC EPI Office, Kinshasa, Democratic Republic of the Congo.
Branly K MbungaKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Aimé M W B CikomolaExpanded Program for Vaccination, Minister of Public Health, Hygiene and Prevention, Kinshasa, Democratic Republic of the Congo.
Anne W RimoinUniversity of California Los Angeles, Department of Epidemiology, CA, Los Angeles, USA.
Jean-Crispin MukendiExpanded Program for Vaccination, Minister of Public Health, Hygiene and Prevention, Kinshasa, Democratic Republic of the Congo.
Jean Bernard LeGargassonGavi, The Vaccine Alliance, Geneva, Switzerland.
Cyril NogierGavi, The Vaccine Alliance, Geneva, Switzerland.
Léon KinuaniWorld Health Organization, DRC EPI Office, Kinshasa, Democratic Republic of the Congo.
Marcellin Mengouo NimpaWorld Health Organization, DRC EPI Office, Kinshasa, Democratic Republic of the Congo.
Daniel K IshosoKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo; World Health Organization, DRC EPI Office, Kinshasa, Democratic Republic of the Congo.
Adèle N MudipanuUNICEF DRC Child Survival Office, Kinshasa, Democratic Republic of the Congo.
Deo ManirakizaUNICEF DRC Child Survival Office, Kinshasa, Democratic Republic of the Congo.
Didine K KabaKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
Jean K NyandweKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
M Carolina Danovaro-HollidayImmunization, Vaccines and Biologicals Department, World Health Organization, Geneva, Switzerland.
Amine El MouridBill and Melinda Gates Foundation, London, United Kingdom.
Paul-Samson D LusambaKinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Funding

World Health Organization 001
6 · The paper itself

Abstract

In the Democratic Republic of the Congo (DRC), estimating vaccine coverage (VC) has traditionally relied on large-scale surveys such as the Demographic and Health Surveys (DHS) and the Multiple Indicator Cluster Surveys (MICS). However, these surveys are infrequent, costly, and lack the granularity needed for decision-making at the health district or zone (HZ) level. This paper describes the development by the Kinshasa School of Public Health (KSPH), and technical partners of a Vaccine Coverage Survey (KSPH VCS), adapted from the World Health Organization (WHO) guidelines, which aims to provides timely, cost-effective, and representative estimates of VC at the HZ level. The KSPH VCS adopted a cross-sectional design and a multi-stage sampling approach to sample households at the HZ level. It uses Health Area as cluster in spite of Enumeration Area, and extends the eligibility age range from 12 -23 months to 6-23 months. The sample size for each HZ was calculated using vaccine coverage provided in MICS-2018. It integrates assessments of barriers and enablers to vaccination. Since 2023, it has included malaria indicators. Since its inception in 2018, it has expanded nationwide, covering all 26 provinces of the DRC by 2022. Findings from the KSPH VCS provides estimates at the HZ level that could be combined to provincial and national estimates. Results have been instrumental in evaluating national immunization strategies, including the Mashako Plan and informing Presidential Forums on immunization. They have informed resource allocation, operational planning, and policy decisions at both national and provincial levels as they provided granularity needed for operational decision-making at the HZ level. Its results have also contributed to global immunization estimates, including the WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). The KSPH VCS demonstrates the feasibility of a locally led, cost-effective, and adaptable VC survey in a low-resource setting. Its success highlights the potential for similar methodologies to be implemented in other low- and middle-income countries seeking to improve immunization monitoring and health system performance.

Indexed as

Immunization ProgramsVaccination CoverageCross-Sectional StudiesDemocratic Republic of the CongoFemaleHumansInfantSurveys and QuestionnairesVaccinationDemocratic Republic of the CongoHealth system strengtheningRoutine immunizationSurvey methodologyVaccination coverage

Identifiers

PMID40031089
PMCPMC12042819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.